CD14 and myeloid sarcoma: We have previously shown that, whereas CD4+/Th17+ and CD4+/PD-1+ T lymphocytes are increased in MS compared to HC (43), CD14+/PD-L1+ monocytes prevail during disease remission (44); this is the immune profile we observed in MS patients undergoing a HV/LP diet.